Table 6.
Tested Parameters |
Patient Groups | Number of Patients (n) |
PACAP-38 Level: Mean +/− SD (pg/mL) |
Significance (p) |
---|---|---|---|---|
IMiDs | Treated | 37 | 199.0 +/− 87.54 | 0.0558 |
Untreated | 21 | 154.3 +/− 40.80 | ||
Lenalidomide | Treated | 18 | 228.6 +/− 95.63 | 0.0062 |
Untreated | 40 | 161.7 +/− 55.43 | ||
Thalidomide | Treated | 14 | 164.9 +/− 38.48 | 0.3083 |
Untreated | 44 | 198.6 +/− 82.59 | ||
Proteasome inhibitor | Treated | 44 | 185.8 +/− 74.11 | 0.4443 |
Untreated | 14 | 198.7 +/− 66.63 | ||
Alkylating agents | Treated | 10 | 141.3 +/− 38.16 | 0.0200 |
Untreated | 48 | 192.8 +/− 71.95 | ||
Steroid | Treated | 45 | 181.0 +/− 66.77 | 0.1582 |
Untreated | 13 | 225.6 +/− 104.8 | ||
Daratumumab | Treated | 4 | 289.6 +/− 150.7 | 0.0773 |
Untreated | 54 | 174.3 +/− 64.45 |